Barclays Reaffirms Equal Weight Rating for Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A)‘s stock had its “equal weight” rating restated by equities research analysts at Barclays in a report released on Friday,Benzinga reports. They presently have a $125.00 price target on the medical research company’s stock. Barclays‘s price target suggests a potential downside of 0.50% from the company’s previous close.

A number of other research firms also recently commented on A. UBS Group decreased their price objective on shares of Agilent Technologies from $150.00 to $130.00 and set a “neutral” rating on the stock in a report on Thursday, May 29th. Wall Street Zen upgraded Agilent Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, June 28th. Evercore ISI dropped their price target on Agilent Technologies from $130.00 to $128.00 and set an “in-line” rating for the company in a research report on Thursday. JPMorgan Chase & Co. dropped their target price on shares of Agilent Technologies from $160.00 to $155.00 and set an “overweight” rating for the company in a report on Thursday, May 29th. Finally, TD Cowen raised their target price on shares of Agilent Technologies to $150.00 and gave the company a “buy” rating in a report on Thursday, May 29th. Six research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $139.25.

Agilent Technologies Price Performance

Agilent Technologies stock opened at $125.63 on Friday. The company has a market cap of $35.69 billion, a P/E ratio of 29.49, a price-to-earnings-growth ratio of 3.82 and a beta of 1.22. Agilent Technologies has a one year low of $96.43 and a one year high of $153.84. The business has a fifty day moving average of $118.39 and a two-hundred day moving average of $116.50. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.60 and a current ratio of 2.25.

Agilent Technologies (NYSE:A) last announced its quarterly earnings results on Wednesday, August 27th. The medical research company reported $1.37 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.37. The business had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a net margin of 17.97% and a return on equity of 25.51%. The business’s revenue was up 10.1% compared to the same quarter last year. During the same quarter last year, the firm posted $1.32 EPS. Agilent Technologies has set its FY 2025 guidance at 5.560-5.590 EPS. Q4 2025 guidance at 1.570-1.600 EPS. As a group, analysts predict that Agilent Technologies will post 5.58 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Agilent Technologies news, CEO Padraig Mcdonnell sold 1,508 shares of the firm’s stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $117.44, for a total transaction of $177,099.52. Following the completion of the transaction, the chief executive officer directly owned 37,448 shares in the company, valued at approximately $4,397,893.12. This trade represents a 3.87% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Institutional Investors Weigh In On Agilent Technologies

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Verdence Capital Advisors LLC grew its holdings in shares of Agilent Technologies by 5.0% during the second quarter. Verdence Capital Advisors LLC now owns 1,818 shares of the medical research company’s stock worth $215,000 after buying an additional 86 shares in the last quarter. M&T Bank Corp grew its holdings in shares of Agilent Technologies by 0.4% during the second quarter. M&T Bank Corp now owns 23,205 shares of the medical research company’s stock worth $2,738,000 after buying an additional 86 shares in the last quarter. CENTRAL TRUST Co boosted its position in shares of Agilent Technologies by 3.7% in the second quarter. CENTRAL TRUST Co now owns 2,522 shares of the medical research company’s stock worth $298,000 after acquiring an additional 89 shares during the last quarter. Burney Co. boosted its position in shares of Agilent Technologies by 4.8% in the second quarter. Burney Co. now owns 1,957 shares of the medical research company’s stock worth $231,000 after acquiring an additional 90 shares during the last quarter. Finally, Valeo Financial Advisors LLC boosted its position in shares of Agilent Technologies by 3.0% in the first quarter. Valeo Financial Advisors LLC now owns 3,449 shares of the medical research company’s stock worth $403,000 after acquiring an additional 102 shares during the last quarter.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.